EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

RANK, RANKL and osteoprotegerin in bone biology and disease



RANK, RANKL and osteoprotegerin in bone biology and disease



Current Reviews in Musculoskeletal Medicine 2(1): 56-64



Upon the discovery of RANK, RANKL and OPG in the late 1990s, their importance in the maintenance of the skeletal structure and their dramatic role in bone disease were largely unexpected. In recent years the understanding of these proteins, in particular their regulation, has greatly increased. This review aims to bring the interested reader up to date with the latest news and views on the mechanisms controlling bone resorption in normal and pathological conditions.

(PDF emailed within 0-6 h: $19.90)

Accession: 055333139

Download citation: RISBibTeXText

PMID: 19468919

DOI: 10.1007/s12178-009-9046-7



Related references

Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women. Menopause 14(5): 913-918, 2007

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Journal of Endocrinological Investigation 32(4 Suppl): 6-9, 2010

The osteoprotegerin/RANK/RANKL system: a bone key to vascular disease. Expert Review of Cardiovascular Therapy 4(6): 801-811, 2006

Role of RANKL-RANK/osteoprotegerin pathway in cardiovascular and bone disease associated with HIV infection. Aids Reviews 16(3): 123-133, 2015

Biology of RANK, RANKL, and osteoprotegerin. Arthritis Research & Therapy 9 Suppl 1: S1-S1, 2007

Receptor Activator of Nuclear Transcription Factor NF-B (RANK), Its Ligand RANKL, and Natural Inhibitor of RANKL Osteoprotegerin (OPG) in the Blood Serum of Patients with Primary Bone Tumors. Bulletin of Experimental Biology and Medicine 163(4): 478-481, 2017

RANK, RANKL and osteoprotegerin in arthritic bone loss. Brazilian Journal of Medical and Biological Research 38(2): 161-170, 2005

Clinical implications of the osteoprotegerin/RANKL/RANK system for bone and vascular diseases. JAMA 292(4): 490-495, 2004

Role of RANKL-RANK/osteoprotegerin molecular complex in bone remodeling and its immunopathologic implications. Indian Journal of Endocrinology and Metabolism 15(3): 175-181, 2011

Effects of osteoprotegerin, RANK and RANKL on bone destruction and collapse in avascular necrosis femoral head. American Journal of Translational Research 8(7): 3133-3140, 2016

The Role of the Osteoprotegerin/RANKL/RANK System in Diabetic Vascular Disease. Current Medicinal Chemistry 18(31): 4813-4819, 2011

The role of the osteoprotegerin/RANKL/RANK system in diabetic vascular disease. Current Medicinal Chemistry 18(31): 4813-4819, 2012

Osteoprotegerin (OPG) and related proteins (RANK, RANKL and TRAIL) in thyroid disease. World Journal of Surgery 35(9): 1984-1992, 2011

The role of RANK/RANKL/osteoprotegerin (OPG) triad in cancer-induced bone diseases: physiopathology and clinical implications. Bulletin du Cancer 98(7): 837-846, 2011

Receptor activator of nuclear factor-κB ligand (RANKL)/RANK/osteoprotegerin system in bone and other tissues (review). Molecular Medicine Reports 11(5): 3212-3218, 2016